Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Terminated
50 enrolled
RE-NEZ-SENS
Phase NA Terminated
5 enrolled
AlloRelapseMM
Phase 3 Terminated
28 enrolled
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
Phase 1 Terminated
6 enrolled
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
23 enrolled
AMBROBiMM
Terminated
3 enrolled
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Phase 2 Terminated
24 enrolled 8 charts
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Phase 2 Terminated
17 enrolled 9 charts
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Phase NA Terminated
2,117 enrolled 6 charts
PROACT
Phase 2 Terminated
49 enrolled 12 charts
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
Phase NA Terminated
21 enrolled
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
24 enrolled
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
CART-38 in Adult AML and MM Patients
Phase 1 Terminated
11 enrolled
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Phase 1/2 Terminated
8 enrolled 8 charts
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Phase 1 Terminated
5 enrolled
FRE
Terminated
105 enrolled
Corneal Findings in Patients Treated With Belantamab Mafodotin
Terminated
12 enrolled
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Phase 2 Terminated
4 enrolled 8 charts
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase 1/2 Terminated
10 enrolled 14 charts
Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy
Phase 2 Terminated
15 enrolled 12 charts
Blood Samples to Identify Biomarkers of Busulfan
Terminated
139 enrolled
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Phase 2 Terminated
1 enrolled 14 charts
DarPAL
Phase 2 Terminated
27 enrolled
EMBRACE
Phase 2 Terminated
1 enrolled 5 charts
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
Phase NA Terminated
12 enrolled 18 charts
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Phase 2 Terminated
3 enrolled 5 charts
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
Phase 1 Terminated
11 enrolled 11 charts
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma
Phase NA Terminated
18 enrolled
Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes
Phase NA Terminated
24 enrolled
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
Phase NA Terminated
3 enrolled
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Phase 1/2 Terminated
23 enrolled 13 charts
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Phase 2 Terminated
17 enrolled
Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
Heart Rate Variability, Vagus Nerve and Cancer
Phase NA Terminated
25 enrolled
The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
Terminated
24 enrolled
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Phase 2 Terminated
5 enrolled 12 charts
MM
Phase NA Terminated
2 enrolled
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Phase 2 Terminated
8 enrolled 8 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Phase 1 Terminated
1 enrolled
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Phase 2 Terminated
9 enrolled 9 charts
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
Phase 1 Terminated
19 enrolled
ClaSPd
Phase 2 Terminated
4 enrolled 9 charts
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase 1/2 Terminated
32 enrolled 18 charts
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Phase 2 Terminated
1 enrolled 9 charts
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
Phase 1/2 Terminated
11 enrolled 11 charts